The role of allergies (A) and tobacco exposure (T) in Obstructive Sleep Apnea Syndrome (OSAS) Type I/II (I/II) in children, and Sublingual Immunotherapy (SLIT) for the treatment of children with OSAS I/II with an Allergic Profile (AP)

Kalomoira Kefala (Ile-de-France, France), Philippe Guerin

Source: Sleep and Breathing Conference 2021

Number: 0

Disease area: Sleep and breathing disorders

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Kalomoira Kefala (Ile-de-France, France), Philippe Guerin. The role of allergies (A) and tobacco exposure (T) in Obstructive Sleep Apnea Syndrome (OSAS) Type I/II (I/II) in children, and Sublingual Immunotherapy (SLIT) for the treatment of children with OSAS I/II with an Allergic Profile (AP). Sleep and Breathing Conference 2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Oral Appliances (OAs) treatment in Obstructive Sleep Apnea (OSA) : a three years experience Source: International Congress 2018 – Treatments that can serve as an alternative to positive airway pressure (PAP) Year: 2018
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016
The sleepy phenotype in mild Obstructive Sleep Apnoea (OSA) patients: from clinical characteristics to cardiometabolic risk. Data from the European Sleep Apnea Database (ESADA). Source: Virtual Congress 2021 – From phenotyping to different diagnostic tools for sleep breathing disorders Year: 2021
Obstructive sleep apnea (OSA) in elderly patients. Role of continuos positive airway pressure (CPAP) treatment. A multicenter randomized controlled clinical trial Source: International Congress 2014 – Three ages of man: OSA in children, adults and the elderly Year: 2014
The impact of depression in patients with severe asthma (SA) in the Wessex Severe Asthma Cohort (WSAC) Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020
Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD) Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Obstructive Sleep Apnea (OSAS) in a clinical cohort of children. Atlantis Study Source: International Congress 2017 – What is new in respiratory and sleep physiology? Year: 2017
LATE-BREAKING ABSTRACT: ORCADES: a prospective cohort study of severe obstructive sleep apnoea (OSA) patients receiving second line-treatment with a mandibular repositioning device (MRD) Source: Annual Congress 2013 –New physiologic boundaries Year: 2013
LATE-BREAKING ABSTRACT: The Sleep Apnea cardioVascular Endpoints (SAVE) study results – A trial of CPAP versus usual care in 2717 high cardiovascular risk patients with moderate-severe obstructive sleep apnea (OSA) Source: International Congress 2016 – Cardiovascular and metabolic pathophysiology and outcomes of obstructive sleep apnoea Year: 2016
LATE-BREAKING ABSTRACT: 2-years follow-up (FU) results of ORCADES study: Long-term mandibular repositioning device (MRD) therapy in patients treated for obstructive sleep apnea (OSA) Source: International Congress 2016 – Non-CPAP in obstructive and central sleep apnoea and obesity hypoventilation syndrome Year: 2016
Prevalence of obstructive sleep apnea (OSA) in patients with lung cancer. Results from the prospective SAIL study Sleep Apnea In Lung Cancer) Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018
Long term changes of C-rective protein (CRP) in obstructive sleep apnoea (OSA) with or without treatment Source: International Congress 2016 – Hypoxia, oxidative stress, and biomarkers in obstructive sleep apnoea Year: 2016
Airway disease and inhaled corticosteroids (ICS) in children with primary ciliary dyskinesia (PCD) Source: International Congress 2016 – Paediatric respiratory infection Year: 2016
Long term effects of compliance with positive airway pressure (PAP) therapy in patients with obesity hypoventilation syndrome (OHS) Source: International Congress 2016 – Treatment options for obstructive sleep apnoea and obesity hypoventilation Year: 2016
The study of small airways' function in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS). Source: International Congress 2017 – Pathophysiological aspects of comorbid conditions in obstructive sleep apnoea Year: 2017
Differences between patients with overlap syndrome (COPD + OSAS) and patients with OSAS Source: International Congress 2015 – Measuring sleep-disordered breathing in children and adults I: questionnaires, epidemiology and sleep studies Year: 2015
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level Source: International Congress 2014 – COPD markers Year: 2014
Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-controlled trials Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016
Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
The ALONNISOS STUDY: Cross-sectional study of the prevalence of Obstructive Sleep Apnea Syndrome (OSAS) and Chronic Obstructive Pulmonary Disease (COPD) in the general population of Alonissos. Source: Virtual Congress 2020 – Phenotyping sleep-disordered breathing and its impact on various diseases Year: 2020